Evaluation of Group CBT Programme With Breast Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00426335|
Recruitment Status : Unknown
Verified January 2010 by Royal Marsden NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : January 24, 2007
Last Update Posted : January 13, 2010
|Condition or disease|
The diagnosis and treatment of cancer is associated with high levels of psychological distress, which can be long-term in duration. The end of adjuvant therapy can be a time which patients find anxiety provoking; as concerns of recurrence and how to return to life after treatment often arise at this juncture.
Cognitive behaviour therapy has demonstrated efficacy in reducing anxiety and depression in people with cancer on a 1:1 basis. The CBT model has been shown to be significantly more beneficial than supportive counselling. Therapy delivered in groups is considered desirable because of its cost effectiveness, and its potential to confer additional benefits in terms of peer support, reduced isolation and modelling of adaptive strategies by other group members.
No studies have looked at the changes in participants health beliefs and beliefs about their ability to copy (self-efficacy) with stress and tolerance of uncertainty following group CBT and the relationship with psychological distress.
The aim of this study is to evaluate a GCBT programme intervention against a waiting list control and to examine its effects on health beliefs, self-efficacy, coping, tolerance of uncertainty and psychological distress in women with early diagnosed breast cancer.
|Study Type :||Observational|
|Estimated Enrollment :||78 participants|
|Official Title:||An Evaluation of a Group CBT Programme for Women With Primary Breast Cancer.|
|Study Start Date :||January 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00426335
|Contact: Maggie Watson, Dr||020 8661 email@example.com|
|Contact: Mary Burgess||020 7808 firstname.lastname@example.org|
|Royal Marsden NHS Foundation Trust||Recruiting|
|London, United Kingdom|
|Contact: Maggie Watson email@example.com|
|Contact: Mary Burgess firstname.lastname@example.org|
|Principal Investigator: Maggie Watson|
|Principal Investigator:||Maggie Watson, Dr||Royal Marsden NHS Foundation Trust|